Results 111 to 120 of about 1,678,519 (353)

Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting?

Therapeutic Advances in Hematology, 2020
Background: Posaconazole prophylaxis during remission induction chemotherapy not only decreases the incidence of invasive aspergillosis (IA) but also improves the overall survival rate among patients with acute myeloid leukemia (AML). However, it remains
Tsung-Chih Chen, Ren Ching Wang, Yu-Hui Lin, Kuang-Hsi Chang, Li-Ya Hung, Chieh-Lin Jerry Teng   +5 more
doaj   +1 more source

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients

Journal of Translational Medicine, 2018
BackgroundAround 30% of patients with inflammatory bowel disease (IBD) are refractory to current IBD drugs or relapse over time. Novel treatments are called for, and low dose Naltrexone (LDN) may provide a safe, easily accessible alternative treatment ...
M. R. Lie, J. van der Giessen, G. Fuhler, A. de Lima, M. Peppelenbosch, C. van der Ent, C. J. van der Woude   +6 more
semanticscholar   +1 more source

Network Localization of Fatigue in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Fatigue is among the most common symptoms and one of the main factors determining the quality of life in multiple sclerosis (MS). However, the neurobiological mechanisms underlying fatigue are not fully understood. Here we studied lesion locations and their connections in individuals with MS, aiming to identify brain networks ...
Olli Likitalo, Jaakko Kungshamn, Albert Bellmunt‐Gil, Silvia Tommasin, Abhineet Ojha, Matias Viitala, Juho Aaltonen, Jyrki Lötjönen, Juha Koikkalainen, Pauli Ylikotila, Patrizia Pantano, Merja Soilu‐Hänninen, Juho Joutsa   +12 more
wiley   +1 more source

Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching

Scientific Reports
There is insufficient evidence comparing the outcomes of tacrolimus-based remission induction therapy with infliximab in refractory ulcerative colitis (UC) and evidence regarding optimal strategies after tacrolimus-based remission induction therapy.
Takeo Yoshihara, Takahiro Amano, Shinichiro Shinzaki, Yuri Tsujii, Akiko Asakura, Taku Tashiro, Mizuki Tani, Yuriko Otake-Kasamoto, Takuya Yamada, Yuko Sakakibara, Naoto Osugi, Shuji Ishii, Satoshi Egawa, Manabu Araki, Yuki Arimoto, Masanori Nakahara, Yoko Murayama, Ichizo Kobayashi, Kazuo Kinoshita, Hiroyuki Ogawa, Satoshi Hiyama, Narihiro Shibukawa, Masato Komori, Yorihide Okuda, Takashi Kizu, Tetsuhisa Kitamura, Minoru Kato, Yoshiki Tsujii, Takahiro Inoue, Hideki Iijima, Yoshito Hayashi, Tetsuo Takehara   +31 more
doaj   +1 more source

MESALAZINE PLACE IN THERAPY OF ULCERATIVE COLITIS

Медицинский совет, 2017
Preparations of 5-aminosalycil acid (Mesalazine) are used as the first-line therapy to induce remission if the UC activity is minimal and as the priority drugs for anti-recurrence therapy of patients with UC and are included in the Russian ...
I. G. Bakulin, M. I. Skalinskaya, E. V. Skazyvaeva   +2 more
doaj   +1 more source

Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells [PDF]

, 2018
Acute inflammation is a complex and tightly regulated homeostatic process that includes leukocyte migration from the vasculature into tissues to eliminate the pathogen/injury, followed by a pro-resolving response promoting tissue repair.
Achuthan, Alivernini, Alivernini, Alvaro-Gracia, Anderson, Asquith, Bamboat, Behrens, Bell, Ben Nasr, Benham, Black, Bluml, Brentano, Burmester, Burmester, Burmester, Catrina, Cauli, Cheung, Chu, Chu, Couzin-Frankel, Cramer, Cross, den Berg, den Brand, Dillon, Donlin, Ehrenstein, Elmesmari, Ferraccioli, Field, Firestein, Frank-Bertoncelj, Gao, Ginhoux, Greven, Guiducci, Guo, Hambleton, Hamilton, Haschka, Herenius, Hogg, Hurst, Iliev, James, Jongbloed, Kaplanski, Kokkonen, Kollias, Konig, Kriegler, Kurowska-Stolarska, Kurowska-Stolarska, Kurowska-Stolarska, Lemke, Malmstrom, Mann, McInnes, McInnes, McInnes, McLoughlin, Midwood, Miller, Misharin, Misso, Moret, Moret, Morton, Murata, Na, Nagy, Nassar, Ng, O'Connell, O'Connell, O'Keeffe, Ohshima, Okada, Paolino, Park, Rajasekhar, Ramwadhdoebe, Rauber, Reynolds, Roberts, Rothlin, Rupaimoole, Rycke, Sacre, Schett, Singh, Smith, Smith, Smolen, Sokolove, Stanczyk, Steidl, Takeuchi, Tannahill, Thai, Tsoumakidou, Udalova, Vandenabeele, Villani, Watts, Weinblatt, Weiss, Williamson, Wolf, Xiong, Yeo, Yu, Zou   +115 more
core   +1 more source

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks, Anna Wolska, Diala Ghazal, Dejan Jakimovski, Bianca Weinstock‐Guttman, Alexander Burnham, Niels Bergsland, Michael G. Dwyer, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +10 more
wiley   +1 more source

Azathioprine-Induced Peripheral T Cell Apoptosis And Drug Response In Patients With Crohn’s Disease [PDF]

, 2011
Background and Aim: the long time interval for a trial of thioupurine therapy and the potential side effects in spite of the proven efficacy, do not encourage their use as early therapeutic option in Crohn’s Disease (CD).
Cossu, Andrea
core  

A new formulation of oral viscous budesonide in treating of paediatric eosinophilic oesophagitis: a pilot study [PDF]

, 2017
OBJECTIVES: Oral viscous budesonide is a recent therapeutic option for eosinophilic oesophagitis (EoE) compared with dietary restriction and inhaled steroids.
Amil, D. J., Cucchiara, S., Isoldi, S., Lucarelli, S., Oliva, S., Papoff, P., Rossetti, D., Rossi, P., Tiberti, A.   +8 more
core   +1 more source